Catalyst Pharmaceuticals (CPRX) Non-Current Assets (2010 - 2026)

Catalyst Pharmaceuticals has reported Non-Current Assets for 17 years, with the latest figure at $207.2 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets fell 7.14% year-over-year to $207.2 million; the trailing twelve-month figure through Mar 2026 stood at $829.5 million (down 9.43% YoY), and the FY2025 full-year result was $209.9 million, down 7.84% from the prior year.
• Non-Current Assets for Q1 2026 stood at $207.2 million, down from $209.9 million in the prior quarter.
• The five-year high for Non-Current Assets was $250.8 million in Q4 2023, with the low at $24.8 million in Q2 2022.
• Historically, Non-Current Assets has averaged $178.4 million across 5 years, with a median of $209.9 million in 2025.
• Annual changes were most pronounced in 2022 — Non-Current Assets fell 27.75% — and 2023, when it jumped 719.88%.
• Catalyst Pharmaceuticals' Non-Current Assets stood at $54.8 million in 2022, then jumped by 357.44% to $250.8 million in 2023, then dropped by 9.16% to $227.8 million in 2024, then fell by 7.84% to $209.9 million in 2025, then fell by 1.3% to $207.2 million in 2026.
• The last three Non-Current Assets figures came in at $207.2 million (Q1 2026), $209.9 million (Q4 2025), and $199.1 million (Q3 2025), per Business Quant data.